Inventaire - dine venner og fællesskaber er dit bedste bibliotek

Myeloproliferative disorders

udgivet i: Blood

dato for udgivelse: 2008-09-01

Cites articles 91

Date

Titel

Forfattere

2008-04

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Ayalew Tefferi
2008-03-06

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

Stefan N Constantinescu
2008-03-11

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

Shu Xing
2008-05-01

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

Linda M. Scott, Wendy Erber, Hans K. Hasselbalch, Georgina Buck, Anthony R Green
2008-06-02

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

Paola Guglielmelli, Giorgina Specchia, Laura Villani, Emanuele Ammatuna, Francesco Lo-Coco
2008-02-01

Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease
2007-11-15

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

Brooke L Fridley
2007-12-26

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Marta Sobas
2007-12-13

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
2007-02-01

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Harvey Lodish, P. Andrew Futreal, Michael Stratton, Mary Frances McMullin
2007-03-15

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

Gianni Tognoni, Leonardo Di Gennaro, Rosamaria Marfisi, Raffaele Landolfi, Valerio De Stefano, Tiziano Barbui
2007-05-01

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation

Paola Guglielmelli, Laura Villani, Alessandro Pancrazzi, Gaetano Bergamaschi, Vittorio Rosti, Alberto Bosi
2007-03-09

The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia

Margherita Massa, Alessandro Pecci, Vittorio Rosti, Paola Guglielmelli, Rita Campanelli
2007-05-01

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

Anna Falanga, Marina Marchetti, Laura Russo
2007-03-15

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
2007-07-01

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis
2007-05-31

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

Ayalew Tefferi
2007-08-30

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling

Heike L. Pahl
2007-12-01

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

Linda M. Scott
2007-11-05

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.

Daniela Pietra, Francesco Passamonti, Robert Kralovics
2006-01-24

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

Martha Wadleigh, Stephanie J. Lee
2006-02-14

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

Thomas Mercher
2006-06-15

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Oliver Ottmann, Andreas Hochhaus, Hagop Kantarjian, Jorge Eduardo Cortes, Susan O'Brien, Francis Giles, Maher Albitar, Kathy Bochinski, Kapil Bhalla, Margaret Dugan, Leila Alland
2006-03-14

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

Francois Delhommeau, William Vainchenker, Myriam Labopin
2006-05-04

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Robert Kralovics
2006-05-02

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis

Didier Pisani, William Vainchenker, Jean-Luc Villeval
2006-05-09

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

Annelise Bennaceur Griscelli, William Vainchenker
2006-09-15

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

Pierre Fenaux, William Vainchenker, Murielle Roussel, Bruno Cassinat, Christine Chomienne, Jean-Jacques Kiladjian, Sylvie Chevret, Pascal Turlure, Nathalie Cambier, Sylvia Bellucci, Marie-Laurence Menot, Philippe Rousselot, Nathalie Parquet, Jean-Didier Rain, Kamel Ghomari
2006-06-13

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia

Anthony R Green
2006-06-27

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

Thomas Mercher, Titus J Boggon
2006-07-25

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

David P. Steensma, Yana Pikman, Ayalew Tefferi, Mark R Litzow
2006-07-27

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Linda M. Scott, Marie-Caroline Le Bousse-Kerdilès

Artikel - wd:Q81943280

Welcome to Inventaire

dit venne- og fællesskabs bibliotek

vil du vide mere